Clinical Trials

Alliance for Clinical Trials in Oncology

https://www.allianceforclinicaltrialsinoncology.org/

23-025

A011801-The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib

EMC-IRB-25-040

A032302: Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial.

EMC-IRB-26-032

OptimICE-PCR: De-Escalation of Therapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients Who Achieve pathological Complete Response (pCR) After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy

EMC-IRB-26-033

A012303 ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade

Key Contacts

Cookie Disclaimer:

By using or otherwise accessing the website, you agree to that this website uses cookies and similar technologies, including those provided by vendors, for various purposes, such as to support website performance, features, and analytics (for example, Google Analytics). These cookies may process data such as IP addresses, including for them to function properly. Cookie vary across the website, including per webpage. For more information, see the Website Privacy Policy. Use or other access to this website is subject to the Website Terms and Conditions.

Accept ALL cookies to enhance your experience, including analytics that help us understand how our site is used. Accept Required allows only essential cookies needed for the website to function, such as session management and your cookie preferences. Accept None does not allow any non-essential cookies and no cookies are stored after your session is complete. Modify My Preferences

Alliance for Clinical Trials in Oncology

Resources

Key Contacts